Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.31 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19984740 | 0.81 | F2RL3 (0.32) | F2RL3 | |
| SCHEMBL21273294 | 0.81 | SUV39H2 (0.33) | F2RL3IKBKETBK1 | |
| SCHEMBL23164753 | 0.76 | IKBKE (0.34) | F2RL3IKBKETBK1 | |
| SCHEMBL19984739 | 0.75 | — | — | |
| SCHEMBL16793408 | 0.75 | IKBKE (0.31) | IKBKETBK1 | |
| SCHEMBL629668 | 0.74 | PDPK1 (0.32) | F2RL3IKBKETBK1 | |
| SCHEMBL21273287 | 0.73 | F2RL3 (0.33) | F2RL3 | |
| SCHEMBL26605652 | 0.71 | SUV39H2 (0.33) | F2RL3IKBKETBK1 | |
| SCHEMBL24130704 | 0.71 | SNCA (0.35) | SNCA | |
| SCHEMBL23204566 | 0.70 | BTK (0.34) | F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929345-B | Substituted pyrazole compounds as TOLL receptor inhibitors | 百时美施贵宝公司 | 2024-07-23 | — | — | CN | disclosed |
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| EP-4051388-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114929345-A | Substituted pyrazole compounds as TOLL receptor inhibitors | 百时美施贵宝公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021087181-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021087181-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | TLR1, TLR3, TLR9 | SNCA 4288/4885F2RL3 219/4885IKBKE 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.